IMI to exhibit at 19th Annual Financial Forum in Toronto

IMI to exhibit at 19th Annual Financial Forum in Toronto 


TORONTO, Jan. 19  /PRNewswire-FirstCall/ -- Predictive medicine company IMI
International Medical Innovations Inc. (TSX: IMI; Amex: IME) today announced
that it will be exhibiting and presenting at the 19th Annual Toronto Financial
Forum, from January 27 - 30, 2005, from 10 a.m. to 5 p.m., at the Metro Toronto
Convention Centre, North Building, Hall "C".

On Thursday, January 27, 2005 at 11:10 a.m. ET, President and Chief Executive
Officer Dr. Brent Norton will make a presentation to attendees on IMI's
business strategy and investment attributes.

"IMI is a growing company with significant potential. Our lead cardiovascular
product is FDA-approved and partnered with McNeil Consumer Healthcare. We have
a multiple product pipeline, strong fundamentals and are poised to generate
revenue," said Dr. Norton. "As we enter 2005, IMI is on the cusp of the most
exciting and dynamic period in its history. This event is an important
opportunity to highlight IMI's investment merits to a broad audience of
investors."

In addition to Dr. Norton's presentation, IMI will conduct skin sterol testing
with PREVU(x) Point of Care Skin Sterol Test, a non-invasive predictive test
for coronary artery disease, throughout the four-day event.

The Financial Forum is a one-stop resource for investment education, ideas and
opportunities. Exhibits showcase public companies as well as leading investment
products and services. The event also features a number of respected financial
speakers. More information about Financial Forum is available at
http://www.financialforum.ca/.

About IMI

IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases. IMI's
cardiovascular products, which are branded as PREVU(x) Skin Sterol Test, will
be marketed and distributed worldwide by McNeil Consumer Healthcare. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. IMI's head office is located in Toronto, and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For further information, please visit http://www.imimedical.com/.

This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-
looking statements. Such risks and uncertainties include, among others, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, the
successful development or marketing of the Company's products, reliance on
third-party manufacturers, the competitiveness of the Company's products if
successfully commercialized, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the protection
offered by the Company's patents and patent applications may be challenged,
invalidated or circumvented by our competitors and there can be no guarantee of
our ability to obtain or maintain patent protection for our products or product
candidates.

Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. IMI is providing
this information as of the date of this press release and does not undertake
any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Company Contact: Sarah Borg-Olivier, Director, Communications,

T: [phone], ; U.S. Investor Contact: Andrea

Faville, The Investor Relations Group, T: [phone],

Copyright